A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 4, 2015, Pages 761-767

  MacMillan, Margaret L ^a   Robin, Marie ^b   Harris, Andrew C ^c   DeFor, Todd E ^a,d   Martin, Paul J ^e   Alousi, Amin ^f,g   Ho, Vincent T ^g,h   Bolaños Meade, Javier ^g,i   Ferrara, James L M ^c,g   Jones, Richard ^g,i   Arora, Mukta ^a   Blazar, Bruce R ^a   Holtan, Shernan G ^a   Jacobsohn, David ^g,j   Pasquini, Marcelo ^g,k   Socie, Gerard ^b   Antin, Joseph H ^g,h   Levine, John E ^c,g   Weisdorf, Daniel J ^a,g  

^a UNIVERSITY OF MINNESOTA   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g Blood and Marrow Transplant Clinical Trials Network GVHD Study Committee   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^k MEDICAL COLLEGE OF WISCONSIN   (United States)

more..

Author keywords

Allogeneic hematopoietic cell transplantation; Grading systems; Graft versus host disease; Risk score; Survival; Transplant related mortality

Indexed keywords

DENILEUKIN DIFTITOX; ETANERCEPT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PLACEBO; PREDNISONE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRAFT VERSUS HOST DISEASE RISK SCORE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; DISEASE SEVERITY; FEMALE; HIGH RISK POPULATION; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; RISK ASSESSMENT; SCORING SYSTEM; STEROID THERAPY; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UMBILICAL CORD BLOOD; ACUTE DISEASE; ADOLESCENT; AGED; ALLOGRAFT; CHILD; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; INFANT; MIDDLE AGED; PRESCHOOL CHILD; RISK FACTOR; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALLOGRAFTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; MALE; MIDDLE AGED; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84924230138     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.01.001     Document Type: Article

References (21)

1. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990, 75:1024-1030.
2. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
3. Martino R., Romero P., Subira M., et al. Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant 1999, 24:283-287.
4. Weisdorf D.J., Hurd D., Carter S., et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003, 9:512-518.
5. Cahn J.Y., Klein J.P., Lee S.J., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005, 106:1495-1500.
6. Levine J.E., Logan B.R., Wu J., et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012, 119:3854-3860.
7. Vander Lugt M.T., Braun T.M., Hanash S., et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. NEngl J Med 2013, 369:529-539.
8. Levine J.E., Harris A.C., Taylor A., et al. Abiomarker-based grading system at onset of GVHD predicts TRM better than the modified Glucksberg Grading System. Blood 2013, 122:145.
9. MacMillan M.L., Defor T.E., Weisdorf D.J. What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol 2012, 157:732-741.
10. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
11. Bolaños-Meade J., Logan B.R., Alousi A.M., et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood 2014, 124(22):3221-3227.
12. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
13. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997, 16:901-910.
14. Cox D.R. Regression models and life tables. JRoyal Stast Soc 1972, 34:187-220.
15. Fine J.P., Gray R.J. Aproportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc 1999, 94:496-509.
16. Breiman L., Freidman J., Olshen R., Stone C. Classification and regression trees 1984, Wadsworth and Brooks, Belmont, CA.
17. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. discussion 207-212.
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
19. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
20. Weisdorf D.J., Snover D.C., Haake R., et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990, 76:624-629.
21. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood 2013, 121:585-594.